This site is intended as a resource for persons who have skin disorders and/or who have visited a dermatologist. We hope it will be interactive. You can find the area you are interested in under the Category Section which is in the right hand column of this page. Please note that we do not accept any money from pharmaceutical companies or device makers. The "A How To Use" page will be helpful.
A landmark study reported in the New England Journal of Medicine highlights the efficacy of a new biologic drug, Dupilumab, for the treatment of atopic dermatitis. This may be heralding a new era for patients with moderate to severe atopic eczema.
This is likely to be a great breakthough for many who suffer moderate to severe atopic dermatitis, but the drug company that makes is will likely play hardball with the pricing. Most biologics today run ~ $50,000 a year. Since Dupilumab may only be taken for four months, the price will be determined by a drug maker keen to maximize its profits. The drug will only be affordable to patients with good insurance. It will not be available to the uninsured or poorly insured.
Promotional photo in NY Times of an ecstatic patient
Abstract: Rarely, human aging can dramatically speed up or slow down, resulting in devastating clinical consequences for patients. Two case histories are presented to illustrate this “relativity” of the human aging process. One patient suffered from progeria and aged rapidly, dying prematurely at 17 years-old. The second patient suffered from syndrome X and seemed not to age at all, remaining a toddler till her death at age 20. Despite their many handicaps, both patients lived inspiring lives that brought much love to their families and friends.
It's normal to feel anxious from time to time, especially if your life is stressful. However, excessive, ongoing anxiety and worry that interfere with day-to-day activities may be a sign of generalized anxiety disorder.
In July 2016, the U. S. Prevention Services Force stated that there is no good evidence for the efficacy of skin cancer screening to prevent death or significant disability. This means that the benefits do not outweigh the potential harm of skin cancer screening.
Nonmelanoma skin cancer comprises 98% of skin cancer's and account for only about .1% of all cancer deaths. Melanoma accounts for about 10,000 cancer deaths a year.
If you have a personal or family history of melanoma, and if you have more than 100 moles you should probably consider being screened. But if not, you could safely pass. A large study in Germany found that skin cancer screening can potentially save one life per hundred thousand individuals screened. It is likely that much more harm could be done from over diagnosis and over treatment in a large screen and population.
Screening picks up small very slow growing or not even growing melanomas that are not destined to harm a patient. However, once they are discovered usually aggressive therapy is recommended and the patient is then labeled as a cancer survivor.
Most dermatologists recommend skin screening. In spite of the lack of evidence for its efficacy, it's good business practice for skin doctors. A skillful dermatologist can find something to treat with cryotherapy or a biopsy on most older caucasians, and this provides a good living for these doctors. It's a low risk screening and a high-value return for dermatologists.
The smart patient should avoid skin cancer screenings if they are not at risk. They should specifically avoid the free skin cancer screenings offered by many hospitals and aggressively promoted by the American Academy of Dermatology. They can just say no. If they have risk factors for skin cancer or are worried about specific lesions they can request a complete skin examination. This may be a good way of alleviating anxiety related to specific skin lesions.
The article in July 26, 2016 New York Times is a good overview. It can be accessed at: http://nyti.ms/2albmU/
"Something strange is going on in medicine. Major diseases, like colon cancer, dementia and heart disease, are waning in wealthy countries, and improved diagnosis and treatment cannot fully explain it.
Scientists marvel at this good news, a medical mystery of the best sort. Many are puzzled as to why." This is a fine introduction to this topic by the science writer, Gina Koilata. Major Diseases are in Decline.
Case report of a 34 yo man with proven Demodex-Rosacea who was treated with 200 mg/kg ivermectin with subsequent weekly topical permethrin. The protocol showed impressive treatment efficacy. See pdf of article: Download Demodeciasis Ivermectin
"A quiet shift is taking place in how women obtain birth control. A growing assortment of new apps and websites now make it possible to get prescription contraceptives without going to the doctor.
The development has potential to be more than just a convenience for women already on birth control. Public health experts hope it will encourage more to start, or restart, using contraception and help reduce the country’s high rate of unintended pregnancies, as well as the rate of abortions."
HZO occurs when latent varicella zoster virus (VZV), residing in the ganglion of the trigeminal nerve, reactivates and affects the ophthalmic nerve (V1). Primary infection with VZV commonly occurs in childhood as chickenpox. Anterior uveitis occurs in 40-50% of all cases of HZO (but only when the tip of the nose is involved).